Energenesis Biomedical Co Ltd
TWSE:6657
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| TW |
E
|
Energenesis Biomedical Co Ltd
TWSE:6657
|
4.2B TWD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
395.1B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
204.9B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
190B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.3B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.5B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.4B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -21 347.1% |
| 30th Percentile | 0.7% |
| Median | 5% |
| 70th Percentile | 11.5% |
| Max | 698% |
Other Profitability Ratios
Energenesis Biomedical Co Ltd
Glance View
Energenesis Biomedical Co., Ltd. engages in the development of new drugs. The company is headquartered in Taipei City, Taipei. The company went IPO on 2018-08-08. The firm's main product projects include experimental service analysis and reagent sales. The firm's main new drugs include ENERGI-F703, ENERGI-F701, ENERGI-F711, and ENERGI-F706. The ENERGI-F703 indications are diabetic foot ulcers. The ENERGI-F701 indications are abnormal alopecia. The ENERGI-F711 indications are burns. The ENERGI-F706 indications are cachexia.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Energenesis Biomedical Co Ltd is -3 499.2%, which is above its 3-year median of -3 658.2%.
Over the last 3 years, Energenesis Biomedical Co Ltd’s Operating Margin has increased from -3 695.9% to -3 499.2%. During this period, it reached a low of -4 079.1% on Jun 30, 2023 and a high of -3 171.8% on Jun 30, 2024.
